Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548275 · ClinicalTrials.gov registry record · Phase 2
Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00548275 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 22 participants.
The verdict
NCT00548275, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The major goal is to determine in patients entering buprenorphine treatment, the prevalence of specific sex-related HIV risk behaviors, their physician's screening of these behaviors and to evaluate the impact of risk reduction counseling.
Interventions
- BEHAVIORAL Enhanced Sexual Risk Management
- BEHAVIORAL Standard Sexual Risk Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548275
The ClinicalTrials.gov registry entry for NCT00548275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced Sexual Risk Management is the first listed.
NCT00548275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548275 about?
NCT00548275 is a clinical study titled "Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence". The major goal is to determine in patients entering buprenorphine treatment, the prevalence of specific sex-related HIV risk behaviors, their physician's screening of these behaviors and to evaluate the impact of risk reduction counseling.
What is the current status of trial NCT00548275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00548275?
The interventions under investigation include: Enhanced Sexual Risk Management (BEHAVIORAL), Standard Sexual Risk Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT00548275?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.